X0202 SCHEDULE 13G/A 0001224962 XXXXXXXX LIVE 3 Common Stock, par value $0.01 per share 03/31/2026 0001130598 Traws Pharma, Inc. 68232V884 12 Penns Trail Newtown PA 18940 Rule 13d-1(c) Perceptive Advisors LLC b DE 0 979815 0 979815 979815 N 6.1 IA Joseph Edelman b X1 0 979815 0 979815 979815 N 6.1 IN Perceptive Life Sciences Master Fund, Ltd. b E9 0 979815 0 979815 979815 N 6.1 CO Traws Pharma, Inc. 12 Penns Trail, Newtown, PA 18940 The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.01 per share (the "Common Stock") of Traws Pharma, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003 Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. Y The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 15,150,669 shares of Common Stock outstanding as of April 24, 2026, as reported in the Issuer's Form 10-K/A filed with the Securities and Exchange Commission on April 30, 2026, and give effect to the exercise of the Warrants (as defined below). Neither Perceptive Advisors nor Mr. Edelman directly hold any shares of Common Stock or Warrants. The Master Fund directly holds 979,815 Warrants immediately exercisable for shares of Common Stock, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) if the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise the Warrants for an aggregate of 979,815 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors. Perceptive Advisors: 6.1% Mr. Edelman: 6.1% Master Fund: 6.1% Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 979,815 Mr. Edelman: 979,815 Master Fund: 979,815 Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 979,815 Mr. Edelman: 979,815 Master Fund: 979,815 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Perceptive Advisors LLC /s/ Joseph Edelman 05/15/2026 Joseph Edelman /s/ Joseph Edelman 05/15/2026 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman 05/15/2026